Related Experiment Video
Updated: Mar 15, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
[Robust treatment planning in proton therapy]
E Sterpin1, A Barragan2, K Souris2
1Katholieke Universiteit Leuven, Department of Oncology, Laboratory of Experimental Radiotherapy, O&N I Herestraat 49, 3000 Leuven, Belgique; Université catholique de Louvain, Center of Molecular Imaging, Radiotherapy and Oncology, institut de recherche expérimentale et clinique, avenue Hippocrate 54, 1200 Brussels, Belgique.
Abstract:
The concentration of the dose delivered by protons at the end of their path, the Bragg peak, has the potential to improve external radiotherapy treatments. Unfortunately, the main strength of the protons, their finite range, is also their greatest weakness. Any uncertainty on the range may lead to inadequate target coverage or excessive toxicity. The uncertainties have multiple origins and include, among others, ballistic errors, morphological modifications or inaccurate estimations of the physical quantities necessary to predict the proton range. Uncertainties have been part of daily practice in conventional radiotherapy with X-rays for a long time. However, dose distributions delivered with X-rays are much less sensitive to uncertainties than the ones delivered with protons. This relative insensitivity enabled the management of uncertainties through safety margins using a simple formalism. The conditions of validity of this formalism are much more restrictive for proton therapy, leading to the need of developing new tools and adapted strategies to manage accurately these uncertainties. The objective of this paper is to present a vision for the management of uncertainties in proton therapy in the continuity of formalisms established for X-rays. The latter are first summarized before discussing the necessary developments in order to consistently apply them to protons.

